Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Multicentre, Parallel Group, Randomised, Controlled Trial to Evaluate the Possible Benefit of Isoniazid Dose Adjustment According to the Genotype for NAT2 (Arylamine N-acetyltransferase Type 2) in Patients With Pulmonary Tuberculosis

NCT00571753 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT00571753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00571753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Multicentre, Parallel Group, Randomised, Controlled Trial to Evaluate the Possible Benefit of Isoniazid Dose Adjustment According to the Genotype for NAT2 (Arylamine N-acetyltransferase Type 2) in Patients With Pulmonary Tuberculosis
Lead sponsor
University of Cologne
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2008
Completion date
February 29, 2012
Enrollment
900 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis